Komori
Share Issuance and Disposal4888STELLA PHARMA CORPORATIONPharmaceuticals

Notice of Completion of Payment for New Shares and Stock Acquisition Rights Issued through the Second Third-Party Allotment under the Share and Stock Acquisition Rights Issuance Program Agreement

Payment for the issuance to CVI Investments, Inc. of 1,000,000 new shares and 10,500 stock acquisition rights in the second private placement has been completed. If all of the stock acquisition rights are exercised, an additional 1,050,000 shares will be issued.

Worth reading
72In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
316000000
Yen (proceeds from the issuance of new shares)
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Issuance of new shares and stock acquisition rights through a third-party allotment

Who receives how much

New shares 1,000,000 common shares / Potential shares underlying the stock acquisition rights 1,050,000 shares (10,500 stock acquisition rights, with each right representing 100 shares)

CVI Investments, Inc.New shares: 1,000,000 shares; stock acquisition rights: 10,500 (underlying shares: 1,050,000)

The lower thin line represents the existing number of shares to which these shares will be added.

New shares ¥316 per share / Stock Acquisition Rights ¥211 per stock acquisition right
Total issue value

New shares: ¥316,000,000; stock acquisition rights: ¥2,215,500

Amount of funds to be raised
New shares: ¥316,000,000. Stock acquisition rights: ¥470,515,500 (¥2,215,500 from the issuance of the stock acquisition rights and ¥468,300,000 from their exercise)
Terms of the stock acquisition rights
Exercise price
The initial exercise price is ¥446 per share. Whether there is an adjustment clause and the adjustment floor are Not disclosed
Exercise period
From 23 June 2026 to 22 June 2030
Number of Stock Acquisition Rights
Total issued: 10,500. Outstanding unexercised balance: Not disclosed
Payment date
22 June 2026
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of new shares and stock acquisition rights through a third-party allotment
Number of shares to be issued or disposed ofNew shares 1,000,000 common shares / Potential shares underlying the stock acquisition rights 1,050,000 shares (10,500 stock acquisition rights, with each right representing 100 shares)
Issue price and disposal priceNew shares ¥316 per share / Stock Acquisition Rights ¥211 per stock acquisition right
Total issue valueNew shares: ¥316,000,000; stock acquisition rights: ¥2,215,500
Amount of funds to be raisedNew shares: ¥316,000,000. Stock acquisition rights: ¥470,515,500 (¥2,215,500 from the issuance of the stock acquisition rights and ¥468,300,000 from their exercise)
Payment date22 June 2026
Intended allotteeName CVI Investments, Inc. / Number of Shares New shares: 1,000,000 shares; stock acquisition rights: 10,500 (underlying shares: 1,050,000)
Exercise priceThe initial exercise price is ¥446 per share. Whether there is an adjustment clause and the adjustment floor are Not disclosed
Exercise periodFrom 23 June 2026 to 22 June 2030
Number of Stock Acquisition RightsTotal issued: 10,500. Outstanding unexercised balance: Not disclosed
Items this document does not state (18)
Estimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company is announcing that the prescribed payment procedures for the second private placement announced on 5 June 2026 have been completed. The purpose of the issuance and the use of proceeds are not provided in this document.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Completion of Payment for New Shares and Stock Acquisition Rights Issued through the Second Third-Party Allotment under the Share and Stock Acquisition Rights Issuance Program Agreement | STELLA PHARMA CORPORATION (4888) timely disclosure | Komori